EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Magnetic Nanoparticle‐Assisted Non‐Viral CRISPR‐Cas9 for Enhanced Genome Editing to Treat Rett Syndrome

Hyeon-Yeol Cho iD, Myungsik Yoo, Thanapat Pongkulapa iD, Hudifah Rabie, Alysson R Muotri iD, Perry T Yin, Jeong-Woo Choi iD, Ki-Bum Lee iD

Advanced Science · 2024-06 · 11 (24)

DOI: 10.1002/advs.202306432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 22.04.2024. Verfasst von Hyeon-Yeol Cho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA. Hauptthemen laut MEDLINE: Rett Syndrome, CRISPR-Cas Systems, Gene Editing. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSF, National Research Foundation of Korea (NRF), NIH Postdoctoral Training for Translating Research in Regenerative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CRISPR‐Cas9 technology has the potential to revolutionize the treatment of various diseases, including Rett syndrome, by enabling the correction of genes or mutations in human patient cells. However, several challenges need to be addressed before its widespread clinical application. These challenges include the low delivery efficiencies to target cells, the actual efficiency of the genome‐editing process, and the precision with which the CRISPR‐Cas system operates. Herein, the study presents a Magnetic Nanoparticle‐Assisted Genome Editing ( MAGE ) platform, which significantly improves the transfection efficiency, biocompatibility, and genome‐editing accuracy of CRISPR‐Cas9 technology. To demonstrate the feasibility of the developed technology, MAGE is applied to correct the mutated MeCP2 gene in induced pluripotent stem cell‐derived neural progenitor cells (iPSC‐NPCs) from a Rett syndrome patient. By combining magnetofection and magnetic‐activated cell sorting, MAGE achieves higher multi‐plasmid delivery (99.3%) and repairing efficiencies (42.95%) with significantly shorter incubation times than conventional transfection agents without size limitations on plasmids. The repaired iPSC‐NPCs showed similar characteristics as wild‐type neurons when they differentiated into neurons, further validating MAGE and its potential for future clinical applications. In short, the developed nanobio‐combined CRISPR‐Cas9 technology offers the potential for various clinical applications, particularly in stem cell therapies targeting different genetic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rett SyndromeCRISPR-Cas SystemsGene EditingHumansInduced Pluripotent Stem CellsMagnetite NanoparticlesMethyl-CpG-Binding Protein 2Genetic Therapy

Stichwörter der Autor:innen

CRISPR‐Cas9Rett syndromegenome editingmagnetic nanoparticlenon‐viral

Substanzen

Magnetite NanoparticlesMethyl-CpG-Binding Protein 2

Autor:innen und Institutionen

  • Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
  • Department of Chemical and Biomolecular Engineering, Sogang University, Seoul, 04107, South Korea.
  • Department of Bio and Fermentation Convergence Technology, Kookmin University, Seoul, 02707, South Korea.
  • W. M. Keck Center for Collaborative Neuroscience and Department of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
  • School of Medicine, Department of Pediatrics/Rady Children's Hospital San Diego, Department of Cellular and Molecular Medicine, Stem Cell Program, La Jolla, CA, 92093, USA.
  • Department of Biomedical Engineering, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.

ORCID-Profile: Hyeon-Yeol Cho, Thanapat Pongkulapa, Alysson R Muotri, Jeong-Woo Choi, Ki-Bum Lee

Förderung

  • NSF
  • National Research Foundation of Korea (NRF)
  • NIH Postdoctoral Training for Translating Research in Regenerative Medicine
  • NINDS NIH HHS
  • NIH RM1
  • NIAMS NIH HHS
  • HealthAdvance
  • CDMRP

Zitieren

APA

Cho, H. Y., Yoo, M., Pongkulapa, T., Rabie, H., Muotri, A. R., Yin, P. T., Choi, J. W., & Lee, K. B. (2024). Magnetic Nanoparticle‐Assisted Non‐Viral CRISPR‐Cas9 for Enhanced Genome Editing to Treat Rett Syndrome. Advanced Science, 11(24). https://doi.org/10.1002/advs.202306432

Vancouver

Cho HY, Yoo M, Pongkulapa T, Rabie H, Muotri AR, Yin PT, et al. Magnetic Nanoparticle‐Assisted Non‐Viral CRISPR‐Cas9 for Enhanced Genome Editing to Treat Rett Syndrome. Advanced Science. 2024;11(24). doi:10.1002/advs.202306432

BibTeX
@article{Cho2024,
  author = {Cho, Hyeon-Yeol and Yoo, Myungsik and Pongkulapa, Thanapat and Rabie, Hudifah and Muotri, Alysson R and Yin, Perry T and Choi, Jeong-Woo and Lee, Ki-Bum},
  title = {Magnetic Nanoparticle‐Assisted Non‐Viral CRISPR‐Cas9 for Enhanced Genome Editing to Treat Rett Syndrome},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {24},
  doi = {10.1002/advs.202306432}
}
Kostenlos starten →